Boehringer Ingelheim India and Lupin enter agreement to market diabetes drug

NEW DELHI: German drug giant Boehringer Ingelheim has entered into an agreement with Mumbai-based Lupin to co-market empagliflozin, a novel drug for the treatment of Type-II diabetes in adults.

According to the agreement, Lupin will market and sell empagliflozin under a separate brand name ‘Gibtulio’, while Boehringer will continue to sell it under the brand name ‘Jardiance’.

The two companies had earlier signed a partnership to co-market another Type-II diabetes drug linagliptin in October 2015.

IMS values the Indian diabetes market is at Rs9,003 crore and has recorded it as growing at 19.5%, according to a release by Lupin.